Evidence-Based Treatment for Advanced Parkinson’ s Disease_Chinese Journal of Evidence-Based Medicine

Authors：

PENG Rong , HE Li

Department of Neurology; West China Hospital; Sichuan University; Chengdu 610041; China;

Corresponding author：

Keywords：

Advanced Parkinson’s disease; On-off; Dyskinesia; Depression; Treatment

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Evidence has been retrieved through MEDLINE and Cochrane Libray about the treatment for patients with advanced Parkinson’s disease who suffered from on-off, dyskinesia and depression after chronic use of L-dopa. All of the evidence has been evaluated. Methods of evidence-based treatment were drawn up according to the evidence, clinciams’ experiences and patients’ preferences. All symptoms of the patient have been improved obviously.

Citation： PENG Rong,HE Li. Evidence-Based Treatment for Advanced Parkinson’ s Disease. Chinese Journal of Evidence-Based Medicine, 2004, 04(3): 210-211. doi: Copy

1.	［1］Hughes AH, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’ s disease: a clinicopathological study of 100 cases [ J ]. J Neurol Neurosurg Psychiatry, 1992; 55: 181-184.
2.	［2］Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality [J]. Neurology, 1967; 17(5): 427-442.
3.	［3］Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H,Stem M, Shoulson 1, Kurlan R, Gtitnes JD, Jankovic J, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease [J].Mov Disord, 1994; 9(1): 40-47.
4.	［4］Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE,Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J.Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’ s disease patients with fluctuating responses to levodopa/carbidopa [J]. Neurology, 1993; 43(10):1981-1984.
5.	［5］inter MM, Pogarell O, Oertel WH, et al. Efficacy safety, and tolerance of the non-ergoline dopamine agonist pramipexole inthe treatment of advanced Parkinson’ s disease: a double blind,placebo controlled, randomised, multicentre study [ J ]. J Neurol Neurosurg Psychiatry, 1999; 66(4): 436-41.
6.	［6］Ziegler M. Efficacy ofpiribedil in adjunction to L-dopa in a 6 month randomized placebo controlled study in early Parkinson’s disease [J ]. Neurology Aeurology. 2000; 54 ( Suppl 3 ).
7.	［7］Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease [J ]. International Pramipexole-Bromocriptine Study Group. Neurology, 1997; 49(4): 1060-1065.
8.	［8］Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F.The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa [ J ]. Clin Neuropharmacol, 2002; 25 ( 1 ): 21-24.
9.	［9］Serrano-Duenas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson’ s disease [J].Rev Neurol, 2002; 35( 11 ): 1010-1014.
10.	［10］Tesei S, AntoniniA, Canesi M, Zecchinelli A, Mariani CB,Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study [J]. Mov Disord, 2000; 15(5): 986-989.
11.	［11］Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease [J ]. Mov Disord, 1997; 12(5): 756-759.

1. ［1］Hughes AH, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’ s disease: a clinicopathological study of 100 cases [ J ]. J Neurol Neurosurg Psychiatry, 1992; 55: 181-184.
2. ［2］Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality [J]. Neurology, 1967; 17(5): 427-442.
3. ［3］Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H,Stem M, Shoulson 1, Kurlan R, Gtitnes JD, Jankovic J, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease [J].Mov Disord, 1994; 9(1): 40-47.
4. ［4］Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE,Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J.Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’ s disease patients with fluctuating responses to levodopa/carbidopa [J]. Neurology, 1993; 43(10):1981-1984.
5. ［5］inter MM, Pogarell O, Oertel WH, et al. Efficacy safety, and tolerance of the non-ergoline dopamine agonist pramipexole inthe treatment of advanced Parkinson’ s disease: a double blind,placebo controlled, randomised, multicentre study [ J ]. J Neurol Neurosurg Psychiatry, 1999; 66(4): 436-41.
6. ［6］Ziegler M. Efficacy ofpiribedil in adjunction to L-dopa in a 6 month randomized placebo controlled study in early Parkinson’s disease [J ]. Neurology Aeurology. 2000; 54 ( Suppl 3 ).
7. ［7］Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease [J ]. International Pramipexole-Bromocriptine Study Group. Neurology, 1997; 49(4): 1060-1065.
8. ［8］Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F.The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa [ J ]. Clin Neuropharmacol, 2002; 25 ( 1 ): 21-24.
9. ［9］Serrano-Duenas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson’ s disease [J].Rev Neurol, 2002; 35( 11 ): 1010-1014.
10. ［10］Tesei S, AntoniniA, Canesi M, Zecchinelli A, Mariani CB,Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study [J]. Mov Disord, 2000; 15(5): 986-989.
11. ［11］Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease [J ]. Mov Disord, 1997; 12(5): 756-759.

Chinese Journal of Evidence-Based Medicine

Evidence-Based Treatment for Advanced Parkinson’ s Disease

Abstract Full text Figures/Tables Video References Cited by

Format

Content